Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
H Döhner, EH Estey, S Amadori… - Blood, The Journal …, 2010 - ashpublications.org
In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …
Therapeutic advances in acute myeloid leukemia
A Burnett, M Wetzler, B Löwenberg - Journal of clinical oncology, 2011 - ascopubs.org
The choice of treatment approach and outcome in acute myeloid leukemia (AML) depends
on the age of the patient. In younger patients, arbitrarily defined as being younger than 60 …
on the age of the patient. In younger patients, arbitrarily defined as being younger than 60 …
Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration
Abstract Background The Reporting Recommendations for Tumor Marker Prognostic
Studies (REMARK) checklist consists of 20 items to report for published tumor marker …
Studies (REMARK) checklist consists of 20 items to report for published tumor marker …
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group …
G Marcucci, K Maharry, YZ Wu… - Journal of clinical …, 2010 - ascopubs.org
Purpose To analyze the frequency and associations with prognostic markers and outcome of
mutations in IDH genes encoding isocitrate dehydrogenases in adult de novo …
mutations in IDH genes encoding isocitrate dehydrogenases in adult de novo …
Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications
G Marcucci, T Haferlach, H Döhner - Journal of Clinical Oncology, 2011 - ascopubs.org
Molecular analyses of leukemic blasts from patients with acute myeloid leukemia (AML)
have revealed a striking heterogeneity with regard to the presence of acquired gene …
have revealed a striking heterogeneity with regard to the presence of acquired gene …
Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in …
T Haferlach, A Kohlmann, L Wieczorek… - Journal of clinical …, 2010 - ascopubs.org
Purpose The Microarray Innovations in Leukemia study assessed the clinical utility of gene
expression profiling as a single test to subtype leukemias into conventional categories of …
expression profiling as a single test to subtype leukemias into conventional categories of …
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute …
D Cilloni, A Renneville, F Hermitte, RK Hills… - Journal of Clinical …, 2009 - ascopubs.org
Purpose Risk stratification in acute myeloid leukemia (AML) is currently based on
pretreatment characteristics. It remains to be established whether relapse risk can be better …
pretreatment characteristics. It remains to be established whether relapse risk can be better …
RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene …
JH Mendler, K Maharry, MD Radmacher… - Journal of clinical …, 2012 - ascopubs.org
Purpose To determine the association of RUNX1 mutations with therapeutic outcome in
younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN …
younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN …
TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Purpose To determine the frequency of TET2 mutations, their associations with clinical and
molecular characteristics and outcome, and the associated gene-and microRNA-expression …
molecular characteristics and outcome, and the associated gene-and microRNA-expression …
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
The associations of mutations in the enhancer of trithorax and polycomb family gene ASXL1
with pretreatment patient characteristics, outcomes, and gene-/microRNA-expression …
with pretreatment patient characteristics, outcomes, and gene-/microRNA-expression …